Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

A Man with End-Stage Renal Disease, Dyspnea, and an Abnormal Echocardiogram.

Schoenberg NC, Ruopp NF, Gupta A, Farber HW.

Ann Am Thorac Soc. 2019 Dec;16(12):1577-1581. doi: 10.1513/AnnalsATS.201904-300CC. No abstract available.

PMID:
31774325
2.

Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents.

McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galié N, Krasuski RA, Preston I, Souza R, Coghlan JG, Frantz RP, Hemnes A, Kim NH, Lang IM, Langleben D, Li M, Sitbon O, Tapson V, Frost A.

Chest. 2019 Nov 16. pii: S0012-3692(19)34214-X. doi: 10.1016/j.chest.2019.10.043. [Epub ahead of print]

3.

Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.

Menon AA, Sahay S, Braverman LE, Farber HW.

Lung. 2019 Dec;197(6):761-768. doi: 10.1007/s00408-019-00283-8. Epub 2019 Nov 6.

PMID:
31696306
4.

Use of ultrasound-measured internal jugular vein collapsibility index to determine static intracardiac pressures in patients with presumed pulmonary hypertension.

Parikh R, Spring M, Weinberg J, Reardon CC, Farber HW.

Ann Intensive Care. 2019 Oct 28;9(1):124. doi: 10.1186/s13613-019-0595-7.

5.

The New World Symposium on Pulmonary Hypertension Guidelines: Should Twenty-One Be the New Twenty-Five?

Ruopp NF, Farber HW.

Circulation. 2019 Oct;140(14):1134-1136. doi: 10.1161/CIRCULATIONAHA.119.040292. Epub 2019 Sep 30. No abstract available.

PMID:
31567011
6.

Add-on parenteral therapy in pulmonary arterial hypertension: The good, the bad, and the ugly.

Schoenberg NC, Farber HW.

J Heart Lung Transplant. 2019 Sep;38(9):1003-1005. doi: 10.1016/j.healun.2019.07.003. Epub 2019 Jul 11. No abstract available.

PMID:
31495406
7.

Swan-Ganz and Pericardial Pressure-guided Pericardiocentesis in Pulmonary Arterial Hypertension-associated Cardiac Tamponade.

Ruopp NF, Schoenberg NC, Farber HW.

Ann Am Thorac Soc. 2019 Sep;16(9):1189-1191. doi: 10.1513/AnnalsATS.201902-127CC. No abstract available.

PMID:
31469306
8.

Pharmacokinetics of ambrisentan in a patient with Pulmonary Arterial Hypertension and a total gastrectomy.

Abston E, Farber HW.

Pulm Pharmacol Ther. 2019 Aug;57:101813. doi: 10.1016/j.pupt.2019.101813. Epub 2019 Jun 12.

PMID:
31199984
9.

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.

Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R.

Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005095. doi: 10.1161/CIRCOUTCOMES.118.005095.

PMID:
31109190
10.

United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications.

Elliott CG, Austin ED, Badesch D, Badlam J, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC.

Pulm Circ. 2019 Apr-Jun;9(2):2045894019851696. doi: 10.1177/2045894019851696.

11.

Barriers to frostbite treatment at an academic medical center.

Khan SL, Parikh R, Mooncai T, Sandhu S, Jawa R, Farber HW.

Am J Emerg Med. 2019 Aug;37(8):1601.e3-1601.e5. doi: 10.1016/j.ajem.2019.05.012. Epub 2019 May 6.

PMID:
31088748
12.

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Humbert M, Farber HW, Ghofrani HA, Benza RL, Busse D, Meier C, Hoeper MM.

Eur Respir J. 2019 Jun 5;53(6). pii: 1802004. doi: 10.1183/13993003.02004-2018. Print 2019 Jun.

13.

Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.

Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, McGoon MD, Pasta DJ, Selej M, Burger CD, Frantz RP.

Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14.

14.

Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease.

Moll M, Christmann RB, Zhang Y, Whitfield ML, Wang YM, Rice L, Stratton E, Lafyatis R, Farber HW.

J Scleroderma Relat Disord. 2018 Oct;3(3):242-248. doi: 10.1177/2397198318764780. Epub 2018 Mar 22.

15.

Response.

Frantz RP, Zhao C, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Mink DR, Selej M, Benza RL.

Chest. 2018 Nov;154(5):1262-1264. doi: 10.1016/j.chest.2018.07.033. No abstract available.

PMID:
30409362
16.

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.

Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V.

J Heart Lung Transplant. 2019 Jan;38(1):43-50. doi: 10.1016/j.healun.2018.09.003. Epub 2018 Sep 12.

17.

Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis.

Rice LM, Mantero JC, Stratton EA, Warburton R, Roberts K, Hill N, Simms RW, Domsic R, Farber HW, Layfatis R.

Arthritis Res Ther. 2018 Aug 16;20(1):185. doi: 10.1186/s13075-018-1679-8.

18.

Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL.

Farber HW, Badesch DB, Benza RL, Elliott CG, Frantz RP, McGoon MD, Selej M, Zhao C, Frost AE.

J Heart Lung Transplant. 2018 Aug;37(8):948-955. doi: 10.1016/j.healun.2018.03.010. Epub 2018 Mar 17.

PMID:
29653800
19.

Case 11-2018: A 48-Year-Old Woman with Recurrent Venous Thromboembolism and Pulmonary Artery Aneurysm.

Farber HW, McDermott S, Witkin AS, Kelly NP, Miloslavsky EM, Stone JR.

N Engl J Med. 2018 Apr 12;378(15):1430-1438. doi: 10.1056/NEJMcpc1800323. No abstract available.

PMID:
29641962
20.

REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat.

Benza RL, Farber HW, Frost A, Grünig E, Hoeper MM, Busse D, Meier C, Nikkho S, Ghofrani HA.

J Heart Lung Transplant. 2018 Jul;37(7):836-843. doi: 10.1016/j.healun.2018.02.015. Epub 2018 Mar 1.

21.

Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?

Farber HW, Benza RL.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):843-845. doi: 10.1164/rccm.201801-0042ED. No abstract available.

PMID:
29373796
22.

Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.

Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL.

Chest. 2018 Jul;154(1):126-135. doi: 10.1016/j.chest.2018.01.009. Epub 2018 Jan 31.

23.

REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival.

Benza RL, Farber HW, Frost A, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM.

J Heart Lung Transplant. 2018 Apr;37(4):513-519. doi: 10.1016/j.healun.2017.11.006. Epub 2017 Nov 11.

24.

Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis.

Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW.

J Heart Lung Transplant. 2018 Jun;37(6):696-705. doi: 10.1016/j.healun.2017.10.028. Epub 2017 Nov 6.

PMID:
29174533
25.

Pulmonary Veno-Occlusive Disease: Welcome to the PAHty (Bostonian for Party).

Miller DP, Farber HW.

Circulation. 2017 Nov 21;136(21):2034-2036. doi: 10.1161/CIRCULATIONAHA.117.031158. No abstract available.

PMID:
29158214
26.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
27.

Assessing risk in pulmonary arterial hypertension: what we know, what we don't.

Benza RL, Farber HW, Selej M, Gomberg-Maitland M.

Eur Respir J. 2017 Aug 3;50(2). pii: 1701353. doi: 10.1183/13993003.01353-2017. Print 2017 Aug. No abstract available.

28.

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.

Raina A, Benza RL, Farber HW.

Pulm Circ. 2017 Jul-Sep;7(3):741-746. doi: 10.1177/2045893217721694. Epub 2017 Aug 3.

29.

A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.

Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML.

Genome Med. 2017 Mar 23;9(1):27. doi: 10.1186/s13073-017-0417-1.

30.

Practical considerations for therapies targeting the prostacyclin pathway.

Farber HW, Gin-Sing W.

Eur Respir Rev. 2016 Dec;25(142):418-430. doi: 10.1183/16000617.0083-2016. Review.

31.

Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.

Sardana M, Moll M, Farber HW.

Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1513-1520. Epub 2016 Nov 4. Review.

PMID:
27756196
32.

Anti-coagulation in pulmonary arterial hypertension: the real blood and guts.

Preston IR, Farber HW.

J Thorac Dis. 2016 Sep;8(9):E1106-E1107. No abstract available.

33.

Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study.

Finch KT, Stratton EA, Farber HW.

J Heart Lung Transplant. 2016 Nov;35(11):1370-1373. doi: 10.1016/j.healun.2016.07.015. Epub 2016 Jul 27. No abstract available.

PMID:
27623099
34.

Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil.

Cheong FY, Gower AC, Farber HW.

Semin Arthritis Rheum. 2017 Feb;46(4):465-472. doi: 10.1016/j.semarthrit.2016.05.015. Epub 2016 Jun 7.

PMID:
27499522
35.

Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)".

Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW.

Circulation. 2016 May 17;133(20):e662. doi: 10.1161/CIRCULATIONAHA.116.022321. No abstract available.

PMID:
27185031
36.

Gestational pulmonary arterial hypertension.

Moll M, Payne JG, Tukey MH, Farber HW.

Pulm Circ. 2015 Dec;5(4):730-3. doi: 10.1086/683689.

37.

The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients.

Lenna S, Assassi S, Farina GA, Mantero JC, Scorza R, Lafyatis R, Farber HW, Trojanowska M.

Arthritis Res Ther. 2015 Dec 16;17:363. doi: 10.1186/s13075-015-0881-1.

38.

Under pressure: pulmonary hypertension associated with left heart disease.

Farber HW, Gibbs S.

Eur Respir Rev. 2015 Dec;24(138):665-73. doi: 10.1183/16000617.0059-2015. Review.

39.

Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension.

Waxman AB, Farber HW.

Circulation. 2015 Dec 1;132(22):2152-61. doi: 10.1161/CIRCULATIONAHA.114.012328. Review. No abstract available.

PMID:
26621638
40.

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW.

Circulation. 2015 Dec 22;132(25):2403-11. doi: 10.1161/CIRCULATIONAHA.115.018435. Epub 2015 Oct 28.

41.

Novel investigational therapies for treating pulmonary arterial hypertension.

Sardana M, Moll M, Farber HW.

Expert Opin Investig Drugs. 2015;24(12):1571-96. doi: 10.1517/13543784.2015.1098616. Epub 2015 Oct 20. Review.

PMID:
26484967
42.
43.

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.

Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A.

Am J Hematol. 2015 Nov;90(11):1060-4. doi: 10.1002/ajh.24174. Epub 2015 Oct 12. Review.

44.

Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I.

Ann Am Thorac Soc. 2015 Jun;12(6):960. doi: 10.1513/AnnalsATS.201505-263LE. No abstract available.

PMID:
26075562
45.

Five-Year outcomes of patients enrolled in the REVEAL Registry.

Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL.

Chest. 2015 Oct;148(4):1043-54. doi: 10.1378/chest.15-0300.

46.

Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost.

Grossman NL, Fiack CA, Weinberg JM, Rybin DV, Farber HW.

Pulm Circ. 2015 Mar;5(1):198-203. doi: 10.1086/679725.

47.

Validation of two predictive models for survival in pulmonary arterial hypertension.

Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemarié JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD.

Eur Respir J. 2015 Jul;46(1):152-64. doi: 10.1183/09031936.00004414. Epub 2015 Apr 2.

48.

Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I.

Ann Am Thorac Soc. 2015 Feb;12(2):269-73. doi: 10.1513/AnnalsATS.201501-020AS.

PMID:
25590376
49.

Are we correctly defining intermediate-risk pulmonary embolism?

Bradford MA, Farber HW.

Chest. 2014 Nov;146(5):e169. doi: 10.1378/chest.14-1362. No abstract available.

PMID:
25367487
50.

Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study.

Frantz RP, Schilz RJ, Chakinala MM, Badesch DB, Frost AE, McLaughlin VV, Barst RJ, Rosenberg DM, Miller DP, Hartline BK, Benton WW, Farber HW.

Chest. 2015 Feb;147(2):484-494. doi: 10.1378/chest.14-1004.

Supplemental Content

Loading ...
Support Center